Key facts
- WASATCH ADVISORS LP filed SCHEDULE 13G/A for Esperion Therapeutics, Inc. Common Stock (ESPR).
- Disclosed ownership: 5.5%.
- Date of event: 31 Mar 2025.
WASATCH ADVISORS LP - 31 Mar 2025 SCHEDULE 13G/A Report for Esperion Therapeutics, Inc. Common Stock (ESPR)
- Filing Manager
- WASATCH ADVISORS LP
- Reporting Manager
- WASATCH ADVISORS LP
- Symbol
- ESPR
- Shares outstanding
- 198,750,127 shares
- Disclosed Ownership
- 10,931,257 shares
- Ownership
- 5.5%
- Form type
- SCHEDULE 13G/A
- Filing time
- 07 Apr 2025, 14:15:51 UTC
- Date of event
- 31 Mar 2025
- Next filing
- 12 Nov 2025
- SEC
- View on sec.gov
Key filing fact
WASATCH ADVISORS LP disclosed 5.5% ownership in Esperion Therapeutics, Inc. Common Stock (ESPR) on 31 Mar 2025.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 07 Apr 2025, 14:15.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (1)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| WASATCH ADVISORS LP | 5.5% | 10,931,257 | 9,839,213 | 0 | Mike Yeates | CEO |
CIK / CUSIP context first